Clascoterone (DB12499): A Comprehensive Pharmacological and Clinical Monograph

Executive Summary

Clascoterone is a first-in-class topical androgen receptor (AR) inhibitor, representing a significant and novel advancement in the management of androgen-mediated dermatological conditions. Marketed under the brand name Winlevi® for its primary indication, acne vulgaris, clascoterone is the first topical therapy to directly target the hormonal pathogenesis of acne at the skin level.[1] Its mechanism of action is predicated on competitive antagonism of dihydrotestosterone (DHT) at the androgen receptor in sebaceous glands and hair follicles, thereby inhibiting downstream signaling pathways that promote sebum production, inflammation, and sebocyte proliferation.[2] This targeted local action distinguishes it from systemic anti-androgen therapies, which are associated with significant systemic side effects.

The innovative nature of clascoterone is rooted in its pharmacokinetic profile. It is designed as a "soft drug" that exerts potent activity at the site of application but undergoes rapid hydrolysis to a significantly less active metabolite, cortexolone, upon minimal systemic absorption. This property ensures a favorable safety profile, characterized by excellent local tolerability comparable to its vehicle cream and a low risk of systemic anti-androgenic effects.[1] Pivotal Phase 3 clinical trials in patients with moderate-to-severe acne vulgaris demonstrated that clascoterone 1% cream, applied twice daily, achieves statistically significant improvements in treatment success rates and reductions in both inflammatory and noninflammatory lesions compared to vehicle.[1] While the magnitude of this effect is modest, its unique mechanism and high tolerability position it as a versatile foundational therapy, suitable for monotherapy in sensitive patients or as part of a combination regimen.

Beyond its approved indication, clascoterone is under active investigation for other androgen-dependent disorders. Most notably, a higher-concentration formulation is in late-stage Phase 3 clinical trials for androgenetic alopecia (AGA), a condition for which no new mechanism of action has been approved in nearly three decades.[2] Emerging evidence also suggests potential utility in conditions such as hidradenitis suppurativa. The successful development of clascoterone for these indications would solidify its status as a platform technology in dermatologic endocrinology and could fundamentally alter the treatment landscape for common hair and skin disorders.

Drug Identification and Physicochemical Properties

A precise and comprehensive identification of a pharmaceutical agent is fundamental to its study and clinical application. This section details the systematic nomenclature, chemical structure, and physicochemical properties of clascoterone.

Systematic Nomenclature and Identifiers

Clascoterone is known by several names and unique identifiers across chemical, regulatory, and research databases. These are essential for accurate cross-referencing and information retrieval.

• DrugBank ID: DB12499 [1]
• Generic Name: Clascoterone [2]
• Chemical Abstracts Service (CAS) Number: 19608-29-8 [1]
• Synonyms and Code Names: The compound is widely referred to in scientific literature and development by its code name, CB-03-01. Other chemical synonyms include cortexolone 17α-propionate and 11-deoxycortisol 17α-propionate. The investigational brand name for its use in androgenetic alopecia is Breezula®.[1]
• **IUPAC Name:**phenanthren-17-yl] propanoate [1]
• InChI Key: GPNHMOZDMYNCPO-PDUMRIMRSA-N [2]

Chemical Structure and Classification

Clascoterone's therapeutic activity is intrinsically linked to its specific molecular structure and chemical class.

• Structural Formula: Clascoterone is a synthetic pregnane steroid. Structurally, it is the C17α propionate ester of the naturally occurring steroid precursor 11-deoxycortisol, which is also known as cortexolone.[1]
• Chemical Class: It belongs to the class of organic compounds known as 21-hydroxysteroids, characterized by a hydroxyl group at the C21 position of the steroid backbone. It is also classified as a pregnenedione.[2]
• Molecular Formula: C24​H34​O5​ [6]
• Molecular Weight: The molecular weight of clascoterone is approximately 402.53 g/mol.[6]

Physicochemical and Formulation Properties

The physical characteristics of clascoterone dictate its formulation as a topical cream and its stability.

• Appearance: In its pure form, clascoterone is a white to almost white crystalline powder.[9]
• Solubility: It is practically insoluble in water but demonstrates solubility in various organic solvents, including dimethylformamide (DMF), dimethyl sulfoxide (DMSO), and ethanol.[8]
• Formulation: Clascoterone is commercially available as Winlevi®, a 1% (10 mg/g) cream. The formulation is a white to almost white cream containing excipients such as cetyl alcohol, propylene glycol, polysorbate 80, mono- and di-glycerides, and purified water, designed to facilitate topical application and skin penetration.[9]
• Stability and Storage: The product requires refrigeration at 2°C to 8°C (36°F to 46°F) prior to being dispensed by a pharmacy. After dispensing, it can be stored at room temperature (20°C to 25°C; 68°F to 77°F) and should be discarded 180 days after the dispensing date or one month after first opening, whichever occurs sooner. The product should not be frozen.[15]

Property	Identifier/Value	Source(s)
DrugBank ID	DB12499	1
Generic Name	Clascoterone	2
CAS Number	19608-29-8	1
Development Code	CB-03-01	1
Molecular Formula	C24​H34​O5​	6
Molecular Weight	402.53 g/mol	6
IUPAC Name	phenanthren-17-yl] propanoate	1
Chemical Class	Synthetic pregnane steroid; 21-hydroxysteroid	1

Table 1: Chemical and Physical Identifiers of Clascoterone. This table provides a consolidated reference for the key identifiers and properties of the clascoterone molecule.

Clinical Pharmacology

The clinical utility of clascoterone is defined by its pharmacodynamic and pharmacokinetic properties. Its unique mechanism of action represents a new paradigm in topical therapy, while its metabolic profile is central to its safety and tolerability.

Pharmacodynamics: Mechanism of Action

Clascoterone is the first approved drug in a new therapeutic class: topical androgen receptor inhibitors. Its mechanism directly addresses the hormonal drivers of acne pathogenesis.[16]

• Primary Mechanism: The fundamental action of clascoterone is as a potent and selective antagonist of the androgen receptor (AR).[1] It exerts this effect locally in the skin, within key cell types such as sebocytes in the sebaceous glands and dermal papilla cells of hair follicles.[2] It functions by competing with high affinity against endogenous androgens, primarily the potent androgen dihydrotestosterone (DHT), for binding to the AR.[2]
• Cellular and Molecular Effects: In normal acne pathogenesis, DHT binds to the AR, forming a complex that dimerizes and translocates to the cell nucleus. There, it acts as a transcription factor, promoting the expression of genes involved in acne development.[2] By competitively binding to the AR, clascoterone prevents DHT from initiating this cascade. This blockade inhibits AR-regulated gene transcription, effectively silencing the androgenic signals that drive the disease process.[2]
• Downstream Physiological Effects: The inhibition of AR-mediated gene transcription translates into three critical physiological effects that counter the formation of acne lesions:

1. Reduced Sebum Production: Androgens are the primary stimulus for sebum production. Clascoterone has been shown in vitro to dose-dependently inhibit androgen-regulated lipid synthesis in human primary sebocytes, directly targeting the overproduction of oil that characterizes acne-prone skin.[2]
2. Reduced Inflammation: Androgens also promote a pro-inflammatory state in the skin. Clascoterone inhibits the production of inflammatory cytokines, such as DHT-induced interleukin-6 (IL-6), from sebocytes and dermal papilla cells, thereby mitigating the inflammatory component of acne lesions.[2]
3. Inhibition of Sebaceous Gland Proliferation: The drug blocks the androgen signaling pathways that stimulate the proliferation and differentiation of sebocytes, helping to normalize the structure and function of the sebaceous gland.[2]

• Comparative Potency: Preclinical and in vitro studies have established the high potency of clascoterone. In bioassays, its topical anti-androgenic activity was found to be equivalent to that of cyproterone acetate and significantly greater than that of progesterone, flutamide, and finasteride.[6] Furthermore, in scalp dermal papilla cells and sebocytes, it is a more efficacious anti-androgen than other AR antagonists like enzalutamide and spironolactone.[1]

The introduction of clascoterone represents a fundamental shift in the strategy for topical acne management. For decades, topical therapies have focused on addressing the downstream consequences of acne pathogenesis. Retinoids target abnormal follicular keratinization, while agents like benzoyl peroxide and topical antibiotics target the proliferation of Cutibacterium acnes and associated inflammation.[21] The primary hormonal driver of the disease—the stimulation of sebaceous glands by androgens—could only be addressed systemically with medications such as oral spironolactone or combined oral contraceptives, which carry a risk of systemic side effects like hyperkalemia, menstrual irregularities, or gynecomastia.[23] Clascoterone is the first therapeutic agent that allows clinicians to directly inhibit this upstream hormonal trigger at the site of action in the skin.[16] This creates an entirely new therapeutic category, providing a targeted, non-antibiotic, non-retinoid option that addresses a core pathogenic factor previously inaccessible to topical treatment. It moves the focus from managing the symptoms of androgen activity to blocking the activity itself, locally and with high specificity.

Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion (ADME)

The pharmacokinetic profile of clascoterone is the key to its innovative design, enabling potent local activity with minimal systemic risk.

• Absorption: Following topical application, clascoterone is formulated to permeate the skin and reach the target dermal structures. However, systemic absorption is minimal.[1] In maximal use pharmacokinetic studies, where subjects applied approximately 6 grams of the 1% cream twice daily (a dose significantly higher than the typical 1 gram), steady-state plasma concentrations were achieved by day five.[1] At steady state, the mean maximum plasma concentration ( Cmax​) was approximately 4.5 ng/mL, with a mean area-under-the-curve (AUCτ​) of 37.1 h*ng/mL.[1]
• Distribution: Once in the systemic circulation, clascoterone is highly bound to plasma proteins (84% to 89%).[2] This high degree of protein binding restricts the amount of free, pharmacologically active drug available to interact with androgen receptors in other parts of the body, further contributing to its localized effect and systemic safety.
• Metabolism: The central element of clascoterone's safety profile is its rapid and extensive metabolism. It is a "soft steroid," designed for potent local action followed by swift inactivation upon entering the systemic circulation. It is rapidly hydrolyzed by ubiquitous esterase enzymes present in the skin and plasma, cleaving the propionate ester to form its primary metabolite, cortexolone (11-deoxycortisol).[2] Cortexolone is a naturally occurring steroid precursor with significantly weaker androgen receptor activity. In clinical studies, plasma concentrations of cortexolone were consistently low, generally at or below the lower limit of quantitation (0.5 ng/mL), confirming the efficiency of this metabolic inactivation pathway.[3]
• Excretion: The complete excretion pathway for clascoterone and its metabolites has not been fully characterized in humans.[2]

The pharmacokinetic properties of clascoterone are not merely incidental but are the core of its therapeutic innovation. The primary challenge in developing steroidal anti-androgens has always been mitigating their systemic side effects.[3] Clascoterone overcomes this hurdle through its chemical design as a propionate ester. This structure makes it an ideal substrate for rapid hydrolysis by esterases, effectively creating a "soft drug" that is active at the target tissue but is quickly metabolized into an inactive form if it reaches the systemic circulation. This elegant pharmacokinetic solution resolves the historical trade-off between the efficacy of anti-androgen therapy and its systemic safety risks. It explains the observation in preclinical studies that clascoterone possesses strong local anti-androgenic activity but negligible systemic effects, allowing for the safe topical application of a potent hormonal agent.[1]

Clinical Evidence and Therapeutic Application in Acne Vulgaris

The approval of clascoterone for acne vulgaris was based on a robust clinical development program that established its efficacy and safety in a large patient population.

Pivotal Phase 3 Clinical Trials: Efficacy Analysis

The cornerstone of the clinical evidence for clascoterone is a pair of large, well-controlled Phase 3 trials.

• Study Design: The efficacy and safety of clascoterone were established in two identical, multicenter, randomized, double-blind, vehicle-controlled Phase 3 clinical trials: CB-03-01/25 (NCT02608450) and CB-03-01/26 (NCT02608476).[4] These studies enrolled a total of 1,440 patients aged 9 years and older (mean age ~20 years) with moderate-to-severe facial acne vulgaris, defined by an Investigator's Global Assessment (IGA) score of 3 or 4 and specific lesion count criteria (30 to 75 inflammatory lesions and 30 to 100 noninflammatory lesions).[1] Participants were randomized to apply either clascoterone 1% cream or a matching vehicle cream to the face twice daily for 12 weeks.[4]
• Primary Efficacy Endpoint (Treatment Success): The primary outcome measure in both trials was the proportion of patients achieving "treatment success" at week 12. This was a composite endpoint, defined as achieving an IGA score of 0 (clear) or 1 (almost clear) combined with at least a 2-point reduction in the IGA score from baseline.[4] Clascoterone demonstrated a statistically significant and consistent benefit over the vehicle cream on this primary endpoint across both studies:
• In trial CB-03-01/25, 18.4% of patients in the clascoterone group achieved treatment success, compared to 9.0% in the vehicle group (p<.001).[4]
• In trial CB-03-01/26, 20.3% of patients in the clascoterone group achieved treatment success, compared to 6.5% in the vehicle group (p<.001).[4]
• Secondary Efficacy Endpoints (Lesion Counts): Clascoterone also demonstrated statistically significant superiority over vehicle in reducing both inflammatory and noninflammatory lesion counts from baseline to week 12.
• Noninflammatory Lesions (NILCs): In trial 1, the mean absolute reduction was -19.4 for clascoterone vs. -13.0 for vehicle. In trial 2, the reduction was -19.4 for clascoterone vs. -10.8 for vehicle.[4]
• Inflammatory Lesions (ILCs): In trial 1, the mean absolute reduction was -19.3 for clascoterone vs. -15.5 for vehicle. In trial 2, the reduction was -20.0 for clascoterone vs. -12.6 for vehicle.[4]
• Long-Term Data: An open-label extension study evaluated the safety and efficacy of clascoterone for up to 12 months. The results indicated that the therapeutic effect was maintained and even improved with continued use. By the end of the study, approximately 50% of patients had achieved clear or almost clear facial skin, supporting its suitability for long-term management of acne.[7]

Outcome Measure (at Week 12)	Trial CB-03-01/25	Trial CB-03-01/26
Primary Endpoint: IGA Treatment Success
Clascoterone 1% Cream	18.4%	20.3%
Vehicle Cream	9.0%	6.5%
p-value	p <.001	p <.001
Secondary Endpoint: Mean Absolute Change in Lesion Counts
Noninflammatory Lesions (Clascoterone vs. Vehicle)	-19.4 vs. -13.0	-19.4 vs. -10.8
Inflammatory Lesions (Clascoterone vs. Vehicle)	-19.3 vs. -15.5	-20.0 vs. -12.6

Table 2: Summary of Efficacy Outcomes from Pivotal Phase 3 Trials of Clascoterone 1% Cream vs. Vehicle at Week 12. Data compiled from multiple sources.[4]

While the clinical trial results demonstrate clear statistical superiority, the absolute success rates of approximately 20% and the magnitude of lesion reduction are considered modest.[16] The number needed to treat (NNT) to achieve one additional successful outcome compared to vehicle is between 7 and 11.[23] This efficacy profile suggests that clascoterone is not a rapid "rescue" therapy for severe acne in the same vein as oral isotretinoin.[23] Instead, its clinical value is more nuanced. Its unique mechanism targets a fundamental pathogenic pathway—the hormonal drive for sebum production—that is not addressed by other topical agents.[33] This positions it as an ideal foundational therapy. It can be used as a well-tolerated first-line agent for patients with mild-to-moderate acne, particularly when a hormonal component is suspected, or as a critical component of a multi-modal regimen for more severe cases. In combination therapy, it can tackle the sebum/hormonal aspect while other agents, such as retinoids or benzoyl peroxide, address follicular hyperkeratinization and bacterial proliferation, respectively. Its excellent tolerability profile further supports its role in long-term, foundational acne management.[34]

Safety, Tolerability, and Adverse Event Profile

Clascoterone is generally well-tolerated, with a safety profile that was comparable to its vehicle cream in pivotal trials.

• Local Skin Reactions: The most frequently reported adverse events are local skin reactions at the site of application. These include erythema/reddening (up to 12.2%), scaling/dryness (up to 10.5%), and pruritus (itching, 7% to 12%).[9] Other less common reactions include edema, stinging, and burning (>3%).[9] A critical finding from the Phase 3 trials was that the incidence and severity of these local reactions were similar between the clascoterone and vehicle groups, indicating that the active drug itself contributes very little to local irritation.[9]
• Systemic Adverse Events: Systemic adverse events were rare in the large-scale efficacy trials.[16] However, maximal use and pharmacokinetic studies have identified two potential systemic effects of note, stemming from the minimal systemic absorption of the drug:

1. Hypothalamic-Pituitary-Adrenal (HPA) Axis Suppression: Due to its steroidal structure and relation to cortexolone, clascoterone has the potential to cause reversible HPA axis suppression. This was observed in a small percentage of subjects in dedicated studies, defined as a post-cosyntropin stimulation serum cortisol level of ≤18 mcg/dL.[2] The incidence was 5% in adults and 9% in adolescents in one trial, and up to 15% in a pediatric maximal use study.[1] Importantly, in all documented cases, HPA axis function returned to normal within four weeks of discontinuing the treatment.[1] The risk is considered higher in pediatric patients, with prolonged use, or with application over large surface areas.[9]
2. Hyperkalemia: Given the structural similarity to the oral anti-androgen spironolactone, which can cause hyperkalemia, potassium levels were monitored. Mild, transient elevations in serum potassium were observed in approximately 5% of clascoterone-treated subjects, a rate that was not significantly different from that observed in the vehicle group (4.7%).[9] The clinical significance of this finding is considered low, and routine blood monitoring is not required for patients using clascoterone.[7]

• Contraindications: There are no contraindications listed in the prescribing information for clascoterone cream.[9]
• Use in Specific Populations:
• Pregnancy and Lactation: There is limited data on the use of clascoterone in pregnant women. In Australia, it has been assigned Pregnancy Category D, indicating a potential risk to the fetus.[1] For lactation, no clinical information is available, but because systemic absorption is low and the drug is highly protein-bound, amounts in breastmilk are expected to be low.[28]
• Pediatric Use: The drug is approved for use in patients 12 years of age and older. Pediatric patients may be more susceptible to systemic toxicity, such as HPA axis suppression, due to a higher body surface area to mass ratio.[9]

Dosing, Administration, and Patient Counseling

Proper use of clascoterone is essential for achieving optimal efficacy and minimizing potential side effects.

• Dosage: The recommended dosage is the application of a thin, uniform layer of approximately 1 gram of the 1% cream to the entire affected area twice daily, once in the morning and once in the evening.[9] The twice-daily dosing regimen was the one proven effective in the pivotal trials; once-daily application has not been studied and is not recommended.[39]
• Administration: The cream should be applied to clean, dry skin. It is intended for topical dermatologic use only and should not be used ophthalmically, orally, or vaginally. Application should be avoided on skin with cuts, abrasions, eczema, or sunburn.[9] Patients should avoid accidental transfer to the eyes, mouth, or other mucous membranes; if contact occurs, the area should be rinsed thoroughly with water.[9]
• Patient Counseling: To minimize the risk of irritation, patients should be advised to limit the concomitant use of other potentially irritating topical products. This includes medicated or abrasive soaps and cleansers, cosmetics with a strong drying effect, and products with high concentrations of alcohol, astringents, spices, or lime.[9]

Comparative Therapeutic Landscape

Clascoterone enters a well-established market for acne therapies. Its clinical value is best understood by comparing its profile to existing standard-of-care treatments.

Positioning Against Topical Retinoids (e.g., Tretinoin)

Topical retinoids are a cornerstone of acne therapy, but their mechanism and tolerability profile differ significantly from clascoterone.

• Mechanism of Action: The two classes of drugs have distinct and complementary mechanisms. Clascoterone is a hormonal pathway inhibitor that reduces sebum production by blocking androgen receptors.[2] Tretinoin and other retinoids are vitamin A derivatives that primarily act by normalizing follicular keratinization, which prevents the formation of microcomedones. They also possess anti-inflammatory properties.[22] Their mechanisms do not overlap, suggesting a strong rationale for combination use.
• Efficacy: Direct, large-scale, head-to-head comparative trials are lacking. However, a small Phase 2 randomized trial involving 77 adult males with mild-to-moderate acne suggested that clascoterone 1% cream had similar overall efficacy to tretinoin 0.05% cream.[16] In this study, clascoterone was numerically superior to tretinoin in achieving IGA success (22% vs. 12%) and was statistically superior to tretinoin in reducing inflammatory lesion counts.[16]
• Tolerability: The most significant differentiator is tolerability. Topical retinoids are notoriously associated with local irritation, including erythema, peeling, dryness, and photosensitivity, which can be a major barrier to patient adherence.[22] In the same Phase 2 trial, clascoterone demonstrated consistently and numerically lower irritancy scores compared to tretinoin throughout the study period.[16] This aligns with the Phase 3 data showing clascoterone's local side effect profile is similar to its inactive vehicle cream.[23]

Positioning Against Benzoyl Peroxide (BPO) and Other Standard Therapies

Clascoterone also offers a distinct profile compared to other common topical agents.

• Mechanism of Action: Benzoyl peroxide is a potent antimicrobial agent that is highly effective against C. acnes and also has mild keratolytic effects.[21] Clascoterone does not possess direct antimicrobial properties. Instead, it targets the hormonal production of sebum, which is the primary substrate for C. acnes proliferation, thus acting further upstream in the pathogenic process.[31]
• Combination Potential: Clascoterone's unique mechanism and excellent tolerability make it an ideal candidate for use in combination regimens. Addressing multiple pathogenic pathways simultaneously is a core principle of modern acne management. In vitro stability studies have confirmed that clascoterone cream is chemically stable when layered with a wide range of other commonly used topical acne medications, including tretinoin, adapalene/BPO combinations, and clindamycin/BPO combinations.[35] This supports its use as part of a comprehensive, multi-targeted treatment plan.

The primary competitive advantage of clascoterone lies not in overwhelming efficacy but in the combination of a novel mechanism with a highly favorable tolerability profile. Poor adherence is a major challenge in the long-term management of acne, often driven by the irritation caused by effective but harsh agents like retinoids and benzoyl peroxide.[31] The fact that clascoterone's local irritation rates are comparable to those of its vehicle cream—essentially a moisturizer—is a profound clinical benefit.[23] This high degree of tolerability can lead to better patient adherence, which is critical for successful outcomes in a chronic disease. While its efficacy as a monotherapy is modest, its ability to be well-tolerated allows it to be easily combined with more potent agents for enhanced efficacy, or to be used as a primary therapy in patients with sensitive skin who cannot tolerate the irritation of traditional first-line treatments. This positions clascoterone as a versatile and foundational tool in the dermatologist's armamentarium, rather than simply another competitor in terms of raw efficacy.

Emerging and Investigational Uses

The mechanism of clascoterone—topical androgen receptor blockade—has therapeutic potential far beyond acne vulgaris. Active research is underway to explore its utility in other common and challenging androgen-mediated dermatoses.

Androgenetic Alopecia (AGA)

The most advanced investigational use for clascoterone is in the treatment of androgenetic alopecia, or common pattern hair loss.

• Rationale: AGA is a classic androgen-dependent condition. It is driven by the action of DHT on genetically susceptible hair follicles in the scalp, which leads to progressive miniaturization of the follicles and shortening of the hair growth cycle.[2] Clascoterone's ability to block androgen receptors in the dermal papilla cells of these follicles directly counters this primary pathogenic mechanism.[2]
• Development Status: Clascoterone is being developed for AGA as a higher-concentration topical solution under the investigational brand name Breezula®.[1] A successful Phase 2 dose-ranging study in males demonstrated statistically significant improvements in Target Area Hair Count (TAHC) compared to vehicle for all doses tested.[5]
• Phase 3 Clinical Trials: Based on the promising Phase 2 results, a large-scale global Phase 3 program was initiated in June 2023.[5] The program consists of two identical, 12-month, randomized, double-blind, vehicle-controlled studies named SCALP1 (NCT05910450) and SCALP2 (NCT05914805).[45] These trials will enroll a total of 1,500 male subjects with AGA, who will apply a 5% clascoterone solution or vehicle to the scalp twice daily.[5] The co-primary endpoints are change in TAHC and a Patient-Reported Outcome (PRO) measure.[5]

Hidradenitis Suppurativa (HS) and Other Androgen-Mediated Conditions

There is growing interest in the off-label and investigational use of clascoterone for other skin conditions where androgens play a role.

• Rationale: Hidradenitis suppurativa is a chronic, debilitating inflammatory skin disease characterized by painful nodules and abscesses in intertriginous areas. There is strong evidence for an androgen-dependent component to HS, involving follicular plugging and sebaceous gland activity.[1] Clascoterone's mechanism is therefore highly relevant to the underlying pathophysiology of HS.
• Clinical Evidence: While not yet studied in large-scale trials, evidence for its use in HS is emerging from case reports and small case series. One series of 12 patients with mild HS treated with topical clascoterone reported clinical improvement in 10 patients (83%), with patients experiencing fewer flares and smaller lesions.[48] Another published case report described a patient with Hurley stage I HS who experienced significant improvement in lesions and pain after just one week of clascoterone monotherapy.[48] Furthermore, real-world case series on the use of clascoterone for acne have reported incidental benefits in patients with comorbid conditions, including HS, facial hirsutism, and folliculitis, further supporting its broad anti-androgenic activity in the skin.[50]

The potential success of clascoterone in androgenetic alopecia would be a transformative event for the drug and the field of dermatology. The current market for male AGA is dominated by oral finasteride (a 5-alpha reductase inhibitor) and topical minoxidil (a vasodilator). While effective, finasteride is associated with systemic sexual side effects that are a significant concern for many patients, leading to treatment hesitation or discontinuation. Clascoterone offers the potential for a therapy that targets the same hormonal pathway as finasteride but does so topically, with minimal systemic risk due to its "soft drug" pharmacokinetics. This would represent the first truly new mechanism of action for AGA in nearly three decades and could capture a substantial portion of the market, particularly among patients who are hesitant to use systemic treatments.[5] An approval in AGA would also provide powerful validation for the topical anti-androgen class and would strongly support further investigation and potential label expansion for other androgen-driven skin and hair conditions like HS, solidifying clascoterone's role as a versatile platform technology in dermatologic endocrinology.

Regulatory and Market Overview

Clascoterone has successfully navigated the regulatory process in several major markets and is now in its commercial phase, though access and cost remain important considerations.

Regulatory History

Clascoterone has received approval from several key international regulatory agencies.

• U.S. Food and Drug Administration (FDA): Clascoterone (Winlevi®) was first approved by the FDA on August 26, 2020, for the topical treatment of acne vulgaris in patients 12 years of age and older.[2] This was a landmark approval, as it was the first acne drug with a new mechanism of action to be approved in the United States in nearly 40 years.[52]
• Health Canada: The drug was approved for the same indication in Canada on June 15, 2023.[14]
• Therapeutic Goods Administration (TGA) of Australia: Approval in Australia was granted on March 8, 2024.[13] Upon approval, it was placed under the TGA's Black Triangle Scheme, which signifies that it is a new medicine subject to additional post-market safety monitoring to gather more real-world data.[13]

Commercial Landscape

The development and commercialization of clascoterone involve a network of specialized pharmaceutical companies.

• Originator and Developer: The drug was originated by Cosmo Pharmaceuticals and developed by its dermatology-focused spin-out company, Cassiopea.[3]
• Commercial Partner and Manufacturer: Sun Pharmaceutical Industries holds the exclusive rights to commercialize Winlevi® in several major markets, including the United States, Australia, Canada, Japan, and Brazil.[10] The active pharmaceutical ingredient (API) for the drug is manufactured exclusively by the contract development and manufacturing organization Curia (formerly AMRI).[52]
• Cost and Market Access: A significant factor influencing the adoption of clascoterone is its high cost. In the United States, the price for a 60-gram tube is approximately $580, which is substantially more expensive than many generic topical acne treatments and oral alternatives like spironolactone (which can cost as little as $10 for a month's supply).[23] This high price point has created barriers to access. For example, some public drug plans, such as Canada's Drug Agency (CDA-AMC), have recommended against reimbursement, citing uncertainty about its comparative effectiveness against less expensive active treatments and its high cost.[55]

Synthesis and Expert Conclusion

The introduction of clascoterone to the dermatologic armamentarium represents a mechanistically driven and significant therapeutic advancement. Its true innovation is twofold: it is the first topical agent to directly target the hormonal pathogenesis of acne, and, more importantly, it achieves this through an elegant pharmacokinetic design. As a "soft drug," it successfully localizes the potent anti-androgenic effects of a steroid to the skin while minimizing systemic exposure and risk, thereby solving a long-standing safety challenge that has historically limited the use of anti-androgens.

In the context of acne vulgaris, while its efficacy as a monotherapy is statistically robust but clinically modest, its value should not be underestimated. Its exceptional tolerability profile, with local irritation rates comparable to its vehicle cream, directly addresses the critical issue of patient adherence, a common failure point for more irritating first-line therapies. This positions clascoterone as a highly versatile agent: it is an excellent option for patients with sensitive skin, a strong foundational therapy for long-term management, and an ideal partner for combination regimens where its unique mechanism can complement traditional agents. The primary obstacle to its widespread adoption is its high acquisition cost, which has led to challenges with reimbursement and patient access.

The future of clascoterone is exceptionally promising and extends far beyond acne. Its potential to redefine the treatment of androgenetic alopecia is profound. If the ongoing Phase 3 SCALP trials are successful, clascoterone could become the first new mechanism of action for hair loss in decades, offering a much-needed topical alternative to systemic therapies and their associated side effects. Such an approval would not only open a major new market but also validate its utility in other androgen-mediated skin disorders like hidradenitis suppurativa. The outcomes of these trials are therefore eagerly awaited and will ultimately determine whether clascoterone transitions from being a novel acne treatment to a blockbuster platform drug in the expanding field of dermatologic endocrinology.

Works cited

1. Clascoterone - Wikipedia, accessed September 29, 2025, https://en.wikipedia.org/wiki/Clascoterone
2. Clascoterone: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed September 29, 2025, https://go.drugbank.com/drugs/DB12499
3. Clascoterone: First Approval - Sci-Hub, accessed September 29, 2025, https://2024.sci-hub.se/8366/04110b9c75a513ca82104904579ed094/dhillon2020.pdf
4. Efficacy and Safety of Topical Clascoterone Cream, 1%, for ..., accessed September 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7177662/
5. Cosmo Announces the Beginning of the Phase III Trials in Males for ..., accessed September 29, 2025, https://www.cosmopharma.com/news/cosmo-announces-the-beginning-of-the-phase-iii-trials-in-males-for-the-treatment-of-androgenetic-alopecia
6. Clascoterone | CAS#19608-29-8 | Antiandrogen | MedKoo, accessed September 29, 2025, https://www.medkoo.com/products/10609
7. Clascoterone: Uses, Side-Effects and More - DermNet, accessed September 29, 2025, https://dermnetnz.org/topics/clascoterone
8. Cortexolone 17α-propionate (CAS 19608-29-8) - Cayman Chemical, accessed September 29, 2025, https://www.caymanchem.com/product/28392/cortexolone-17%CE%B1-propionate
9. This label may not be the latest approved by FDA. For current ..., accessed September 29, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213433s000lbl.pdf
10. Clascoterone - Cosmo Pharmaceuticals - AdisInsight - Springer, accessed September 29, 2025, https://adisinsight.springer.com/drugs/800026561
11. Compound: CLASCOTERONE (CHEMBL3590187) - ChEMBL - EMBL-EBI, accessed September 29, 2025, https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL3590187
12. Clascoterone ≥98% (HPLC) - Sigma-Aldrich, accessed September 29, 2025, https://www.sigmaaldrich.com/US/en/product/sigma/sml3084
13. Winlevi (clascoterone) | Therapeutic Goods Administration (TGA), accessed September 29, 2025, https://www.tga.gov.au/resources/auspmd/winlevi-clascoterone
14. PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION, accessed September 29, 2025, https://pdf.hres.ca/dpd_pm/00071308.PDF
15. Clascoterone Topical Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed September 29, 2025, https://www.drugs.com/dosage/clascoterone-topical.html
16. Clascoterone (WINLEVI) Cream National Drug Monograph April 2022 - VA.gov, accessed September 29, 2025, https://www.va.gov/formularyadvisor/DOC_PDF/MON_Clascoterone_WINLEVI_Cream_in_Acne_Apr_2022.pdf
17. Is Clascoterone approved by the FDA? - Patsnap Synapse, accessed September 29, 2025, https://synapse.patsnap.com/blog/is-clascoterone-approved-by-the-fda
18. www.guidetopharmacology.org, accessed September 29, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11215#:~:text=Comment%3A%20Clascoterone%20is%20a%20steroidal,cytokines%20from%20sebocytes%20%5B4%5D.
19. Sun Pharmaceuticals announces approval of Winlevi® in Australia, accessed September 29, 2025, https://sunpharma.com/wp-content/uploads/2024/03/Press-Release-Winlevi-Approval-in-Australia.pdf
20. go.drugbank.com, accessed September 29, 2025, https://go.drugbank.com/drugs/DB12499#:~:text=By%20blocking%20the%20interaction%20between,%2Dinduced%20IL%2D6%20synthesis.&text=Upon%20topical%20application%2C%20clascoteronet%20permeates,levels%20with%20minimal%20systemic%20absorption.
21. Nonprescription acne treatment: Which products work best? - Mayo Clinic, accessed September 29, 2025, https://www.mayoclinic.org/diseases-conditions/acne/in-depth/acne-treatments/art-20045814
22. Acne Treatment: A Complete Guide (With Images) - GoodRx, accessed September 29, 2025, https://www.goodrx.com/conditions/acne/acne-treatment-guide
23. Clascoterone (Winlevi) for the Treatment of Acne - AAFP, accessed September 29, 2025, https://www.aafp.org/pubs/afp/issues/2021/0700/p93.html
24. Clascoterone for acne - Australian Prescriber - Therapeutic Guidelines, accessed September 29, 2025, https://australianprescriber.tg.org.au/articles/clascoterone-for-acne.html
25. Caregiver Information | WINLEVI® (clascoterone) cream 1%, accessed September 29, 2025, https://www.winlevi.com/caregiver-information
26. Pharmacokinetic Profile, Safety, and Tolerability of Clascoterone (Cortexolone 17-alpha propionate, CB-03-01) Topical Cream, 1% in Subjects With Acne Vulgaris: An Open-Label Phase 2a Study - JDDonline, accessed September 29, 2025, https://jddonline.com/articles/pharmacokinetic-profile-safety-and-tolerability-of-clascoterone-cortexolone-17-alpha-propionate-cb-0-S1545961619P0563X
27. Full article: Androgen Receptor Inhibitors in the Treatment of Acne Vulgaris: Efficacy and Safety Profiles of Clascoterone 1% Cream [Letter], accessed September 29, 2025, https://www.tandfonline.com/doi/full/10.2147/CCID.S451433
28. Clascoterone - Drugs and Lactation Database (LactMed®) - NCBI Bookshelf, accessed September 29, 2025, https://www.ncbi.nlm.nih.gov/books/NBK588734/
29. A Phase 1 Study to Investigate the Effects of Cortexolone 17α‐Propionate, Also Known as Clascoterone, on the QT Interval Using the Meal Effect to Demonstrate ECG Assay Sensitivity - PMC, accessed September 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8251570/
30. Clascoterone Completed Phase 3 Trials for Acne Vulgaris Treatment | DrugBank Online, accessed September 29, 2025, https://go.drugbank.com/drugs/DB12499/clinical_trials?conditions=DBCOND0029828&phase=3&purpose=treatment&status=completed
31. Clascoterone: a new topical acne medication - Medicine Today, accessed September 29, 2025, https://medicinetoday.com.au/mt/2024/september/regular-series/clascoterone-new-topical-acne-medication
32. View of Clascoterone (Winlevi) - Canadian Journal of Health Technologies, accessed September 29, 2025, https://canjhealthtechnol.ca/index.php/cjht/article/view/SR0863/2384
33. How Is Winlevi Different from Other Types of Acne Creams? - GoodRx, accessed September 29, 2025, https://www.goodrx.com/winlevi/winlevi-acne-cream
34. Clinical Review - Clascoterone (Winlevi) - NCBI Bookshelf, accessed September 29, 2025, https://www.ncbi.nlm.nih.gov/books/NBK616783/
35. Clascoterone Cream 1% Deemed Stable When Combined With Other Topical Acne Treatments | Dermatology Times, accessed September 29, 2025, https://www.dermatologytimes.com/view/clascoterone-cream-1-deemed-stable-when-combined-with-other-topical-acne-treatments
36. Winlevi Side Effects: Common, Severe, Long Term - Drugs.com, accessed September 29, 2025, https://www.drugs.com/sfx/winlevi-side-effects.html
37. Twice Daily Dosing | WINLEVI® (clascoterone) cream 1% for HCPs, accessed September 29, 2025, https://www.winlevi-hcp.com/daily-dosing
38. Clascoterone (Professional Patient Advice) - Drugs.com, accessed September 29, 2025, https://www.drugs.com/ppa/clascoterone.html
39. Efficacy | WINLEVI® (clascoterone) cream 1% for HCPs, accessed September 29, 2025, https://www.winlevi-hcp.com/efficacy
40. Winlevi (clascoterone) FDA Approval History - Drugs.com, accessed September 29, 2025, https://www.drugs.com/history/winlevi.html
41. A Randomized, Double-blind, Split-face Study Comparing the Efficacy and Tolerability of Three Retinol-based Products vs. Three Tretinoin-based Products in Subjects With Moderate to Severe Facial Photodamage - JDDonline, accessed September 29, 2025, https://jddonline.com/a-randomized-double-blind-split-face-study-comparing-the-efficacy-and-tolerability-of-three-retinol-based-products-vs-three-tretinoin-based-products-in-subjects-with-moderate-to-severe-facial-photodam/
42. Winlevi vs. Tretinoin for Acne: Important Differences and Potential ..., accessed September 29, 2025, https://www.goodrx.com/compare/winlevi-vs-tretinoin
43. Fall Clinical News: Clascoterone Cream 1% (Winlevi) Reduces Sebum Levels, Demonstrates Stability When Used With Other Acne Meds - The Dermatology Digest, accessed September 29, 2025, https://thedermdigest.com/fall-clinical-news-clascoterone-cream-1-winlevi-reduces-sebum-levels-shows-stability-when-used-with-other-acne-meds/
44. Prospective Pilot Evaluation of the Safety, Tolerability, and Efficacy of Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel plus Clascoterone 1% Cream in Adult Patients with Acne | JCAD - The Journal of Clinical and Aesthetic Dermatology, accessed September 29, 2025, https://jcadonline.com/treatments-adult-patients-with-acne/
45. NCT05910450 | A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss | ClinicalTrials.gov, accessed September 29, 2025, https://www.clinicaltrials.gov/study/NCT05910450
46. NCT05914805 | A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss (SCALP2) | ClinicalTrials.gov, accessed September 29, 2025, https://clinicaltrials.gov/study/NCT05914805
47. Clascoterone Recruiting Phase 3 Trials for Androgenetic Alopecia (AGA) Treatment, accessed September 29, 2025, https://go.drugbank.com/drugs/DB12499/clinical_trials?conditions=DBCOND0064452&phase=3&purpose=treatment&status=recruiting
48. www.hs\-foundation.org, accessed September 29, 2025, https://www.hs-foundation.org/for-clinicians/prior-authorization-templates?download_file=eyJpZCI6IjEwMDQ1NiJ9
49. Clascoterone Cream 1% in Acne Management: Case Series and Real-World Canadian Experience, accessed September 29, 2025, https://canadiandermatologytoday.com/article/view/6-1-Loo
50. Real-World Experience of Clascoterone Cream 1% in Acne Management: Cas | CCID, accessed September 29, 2025, https://www.dovepress.com/real-world-experience-of-clascoterone-cream-1-in-acne-management-case--peer-reviewed-fulltext-article-CCID
51. Real-World Experience of Clascoterone Cream 1% in Acne Management: Case Series and Canadian Experience - PMC, accessed September 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11760757/
52. AMRI Named Exclusive API Supplier for Recently Approved Acne Treatment - Curia Global, accessed September 29, 2025, https://curiaglobal.com/about-us/news/amri-named-exclusive-api-supplier-for-recently-approved-acne-treatment/
53. B.C. PharmaCare Drug Information Sheet for clascoterone (Winlevi) - Gov.bc.ca, accessed September 29, 2025, https://www2.gov.bc.ca/assets/gov/health/health-drug-coverage/pharmacare/your-voice-drug-info/clascoterone_winlevi_3941_dis.pdf
54. Sun Pharma Receives Australian TGA Approval for Winlevi - Clival Database, accessed September 29, 2025, https://clival.com/news/sun-pharma-receives-australian-tga-approval-for-winlevi
55. Clascoterone (Winlevi) - NCBI Bookshelf, accessed September 29, 2025, https://www.ncbi.nlm.nih.gov/books/NBK612728/
56. Clascoterone (Winlevi) - Canada's Drug Agency, accessed September 29, 2025, https://www.cda-amc.ca/sites/default/files/DRR/2025/SR0863_Winlevi_FINAL_Reconsideration.pdf